Product Images Imatinib Mesylate
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Imatinib Mesylate NDC 62135-659 by Chartwell Rx, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
This document appears to be a table illustrating the results of a study involving patients taking Imatinib Mesylate Tablets and IFNsAC. The data includes the number of patients with progression, the number of patients censored at discontinuation or last follow-up, hazard ratio with confidence intervals, and the Log-rank test result. The information is presented over a period of months since randomization.*
This section of text appears to contain statistical data related to the progression of patients to accelerated phase (AP) or blast crisis (BC) while on treatment with Imatinib Mesylate tablets and IFN+AraC. The hazard ratio and logrank test results are provided, along with the number of patients at risk over a period of months since randomization. It seems to be a part of a clinical study or trial evaluation.*
This text provides data on the recurrence-free survival in Study 2, with details on event survival time in months. The figure shows values and the probability of recurrence-free survival over time for the ITT population.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.